News and Events

Latest News

Stay up to date on Relief activities

Here you will find latest news, upcoming events and interviews.

Corporate News

Archive

Relief Reports Half-Year 2021 Results and Provides Corporate Update

24 September 2021 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics’ Wholly Owned Subsidiary, APR Applied Pharma Research, Reports Data Published in the Peer Reviewed Journal, Nutrients, Indicating Additional Potential Benefits of Its Physiomimic™ Technology

21 September 2021 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Provides Update on Regulatory Interactions in the United Kingdom and European Union Relating to Lead Drug Candidate, RLF-100 (Aviptadil)

13 September 2021 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics’ Wholly Owned Subsidiary, APR Applied Pharma Research, Launches PKU GOLIKE® KRUNCH in Germany and Italy

09 September 2021 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

08 September 2021
Relief Therapeutics Comments on Certain Statements Made by NRx Pharmaceuticals in its Registration Statement on Form S-1 Filed on September 3, 2021

07 September 2021 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Reports Regulatory Clearance in Germany to Commence a Multicenter, Double-blind, Randomized Phase 2 Clinical Trial to Evaluate Inhaled Aviptadil for the Treatment of Sarcoidosis

02 September 2021 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Reports that its U.S. Collaboration Partner has Announced a New Finding from the ZYESAMI™ (aviptadil) Phase 2b/3 Clinical Trial Demonstrating Clinically Significant Relief from Respiratory Distress in Critical COVID-19

31 August 2021 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Reports that its U.S. Collaboration Partner has Announced a Positive Safety Report for ZYESAMI™ (aviptadil) in NIH Sponsored ACTIV-3 Critical Care Study in Patients with Life-Threatening COVID-19

19 August 2021 | Ad Hoc Announcement pursuant to Art. 53 LR
Acer Therapeutics and Relief Therapeutics Announce Submission of a New Drug Application to the U.S. FDA for ACER-001 for Treatment of Urea Cycle Disorders

09 August 2021 | Ad Hoc Announcement pursuant to Art. 53 LR

Events and Presentations

H.C. Wainwright 23rd Annual Global Investment Conference - September 13 - 15, 2021

Monday, September 13, 2021

7:00am EST

Listen to Webcast

Download the Presentation

Scientific References

RLF-100™

Media Contact

For media inquiries contact:

Rx Communication Group
Michael Miller
Mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel.: 917.633.6086

Latest News

Corporate News

Archive

Relief Reports Half-Year 2021 Results and Provides Corporate Update

Relief Therapeutics’ Wholly Owned Subsidiary, APR Applied Pharma Research, Reports Data Published in the Peer Reviewed Journal, Nutrients, Indicating Additional Potential Benefits of Its Physiomimic™ Technology

Relief Therapeutics Provides Update on Regulatory Interactions in the United Kingdom and European Union Relating to Lead Drug Candidate, RLF-100 (Aviptadil)

Relief Therapeutics’ Wholly Owned Subsidiary, APR Applied Pharma Research, Launches PKU GOLIKE® KRUNCH in Germany and Italy

Relief Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

Relief Therapeutics Comments on Certain Statements Made by NRx Pharmaceuticals in its Registration Statement on Form S-1 Filed on September 3, 2021

Relief Reports Regulatory Clearance in Germany to Commence a Multicenter, Double-blind, Randomized Phase 2 Clinical Trial to Evaluate Inhaled Aviptadil for the Treatment of Sarcoidosis

Relief Reports that its U.S. Collaboration Partner has Announced a New Finding from the ZYESAMI™ (aviptadil) Phase 2b/3 Clinical Trial Demonstrating Clinically Significant Relief from Respiratory Distress in Critical COVID-19

Relief Reports that its U.S. Collaboration Partner has Announced a Positive Safety Report for ZYESAMI™ (aviptadil) in NIH Sponsored ACTIV-3 Critical Care Study in Patients with Life-Threatening COVID-19

Acer Therapeutics and Relief Therapeutics Announce Submission of a New Drug Application to the U.S. FDA for ACER-001 for Treatment of Urea Cycle Disorders

Events and Presentations

H.C. Wainwright 23rd Annual Global Investment Conference - September 13 - 15, 2021

Scientific References

RLF-100™

Media Contact

Company

Pipeline

Investor Relations

News and Events